| 1 |
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah‐Eddin Al‐Batran et al. · The Lancet
|
11 Apr 2019 |
2,700 |
| 2 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al. · The Lancet Oncology
|
31 Jul 2014 |
1,759 |
| 3 |
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet
|
19 Feb 2013 |
1,515 |
| 4 |
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Joseph Antonia et al. · The Lancet Oncology
Open access |
5 Jun 2016 |
1,263 |
| 5 |
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung Thi Le et al. · Journal of Clinical Oncology
Open access |
14 Nov 2019 |
1,038 |
| 6 |
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
Heikki Joensuu et al. · JAMA
|
27 Mar 2012 |
982 |
| 7 |
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew David Hellmann, Margaret K. Callahan, Mark Magdi Awad et al. · Cancer Cell
Open access |
May 2018 |
913 |
| 8 |
International consensus statement on the peri‐operative management of anaemia and iron deficiency
Manuel Múñoz, Austin George Acheson, Michael Auerbach et al. · Anaesthesia
Open access |
20 Dec 2016 |
876 |
| 9 |
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Salah‐Eddin Al‐Batran, Joerg Thomas Hartmann, Stephan Probst et al. · Journal of Clinical Oncology
|
18 Mar 2008 |
788 |
| 10 |
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1
Marie Marchand et al. · International Journal of Cancer
|
18 Jan 1999 |
788 |
| 11 |
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah‐Eddin Al‐Batran et al. · The Lancet Oncology
|
22 Oct 2016 |
751 |
| 12 |
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
Elke Jäger, Yao-Tseng Chen, Jan Wouter Drijfhout et al. · The Journal of Experimental Medicine
Open access |
19 Jan 1998 |
731 |
| 13 |
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Annika Nelde et al. · Nature Immunology
Open access |
30 Sep 2020 |
647 |
| 14 |
Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4 + regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda et al. · Proceedings of the National Academy of Sciences
Open access |
14 Oct 2013 |
632 |
| 15 |
Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines
Lawrence T. Goodnough, Alice G. Maniatis, Peter H. Earnshaw et al. · British Journal of Anaesthesia
Open access |
10 Dec 2010 |
545 |
| 16 |
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology
Open access |
23 Jul 2018 |
508 |
| 17 |
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A. Wainberg, Davide Melisi, Teresa Mercade Macarulla et al. · The Lancet
Open access |
11 Sep 2023 |
504 |
| 18 |
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu, Jaffer A. Ajani, Yu-Xian Bai et al. · Journal of Clinical Oncology
Open access |
17 Sep 2013 |
500 |
| 19 |
Biochemical Markers and Hematologic Indices in the Diagnosis of Functional Iron Deficiency
Christian Thomas, Lothar Thomas · Clinical Chemistry
|
Jul 2002 |
493 |
| 20 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer
Salah‐Eddin Al‐Batran et al. · JAMA Oncology
Open access |
27 Apr 2017 |
485 |
| 21 |
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
Sacha Gnjatic, Hiroyoshi Nishikawa, Achim A. Jungbluth et al. · Advances in cancer research
Book chapter |
2006 |
458 |
| 22 |
The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes
Davide F. Robbiani, Rick A. Finch, Dirk Jäger et al. · Cell
Open access |
Nov 2000 |
458 |
| 23 |
Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma
Mathias Rummel, Salah Eddin Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology
Open access |
20 May 2005 |
442 |
| 24 |
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
Elke Jäger, Sacha Gnjatic, Yasuhiro Nagata et al. · Proceedings of the National Academy of Sciences
Open access |
10 Oct 2000 |
426 |
| 25 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al. · The Lancet Oncology
|
2 Sep 2016 |
424 |
| 26 |
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3
Marie-Claude Marchand et al. · International Journal of Cancer
|
11 Dec 1995 |
420 |
| 27 |
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Simon Tiberi, Nelita du Plessis, Gerhard Walzl et al. · The Lancet Infectious Diseases
Open access |
23 Mar 2018 |
410 |
| 28 |
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Kohei Shitara et al. · The Lancet Oncology
Open access |
19 Dec 2023 |
384 |
| 29 |
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Uğur Şahin, Ö. Türeci, Georgy Moiseevich Manikhas et al. · Annals of Oncology
Open access |
21 Feb 2021 |
380 |
| 30 |
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F. Farago, Filippo de Braud et al. · Journal of Thoracic Oncology
Open access |
10 Oct 2018 |
380 |
| 31 |
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Frank Hartmann et al. · Oncology Research and Treatment
|
2003 |
374 |
| 32 |
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
Yelena Yuriy Janjigian, Dominique Werner, Claudia Pauligk et al. · Annals of Oncology
Open access |
12 Jun 2012 |
367 |
| 33 |
Validity of the Six-Minute Walk Test in Cancer Patients
Katharina Schmidt, Lutz Vogt, Christian Thiel et al. · International Journal of Sports Medicine
|
26 Feb 2013 |
364 |
| 34 |
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V.T. Catenacci et al. · The Lancet Oncology
Open access |
25 Sep 2017 |
349 |
| 35 |
Gallbladder carcinoma: Prognostic factors and therapeutic options
Thorsten Oliver Goetze · World Journal of Gastroenterology
Open access |
2015 |
343 |
| 36 |
A Multiplex Polymerase Chain Reaction Protocol for the Simultaneous Analysis of the GlutathioneS-Transferase GSTM1 and GSTT1 Polymorphisms
Michael Arand, Roland Mühlbauer, Jan Georg Hengstler et al. · Analytical Biochemistry
|
Apr 1996 |
339 |
| 37 |
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal Ready, Patrick Alexander Ott, Matthew David Hellmann et al. · Journal of Thoracic Oncology
Open access |
17 Oct 2019 |
330 |
| 38 |
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Georg Wolf, Robert Elez, A Doermer et al. · Oncogene
|
6 Feb 1997 |
327 |
| 39 |
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Yelena Yuriy Janjigian et al. · New England Journal of Medicine
|
Jun 2025 |
311 |
| 40 |
Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
Elke Jäger, Mark Ringhoffer, M. Altmannsberger et al. · International Journal of Cancer
|
10 Apr 1997 |
305 |
| 41 |
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo
Elke J�ger, Mark Ringhoffer, Hans Peter Dienes et al. · International Journal of Cancer
|
3 Jul 1996 |
297 |
| 42 |
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library
Yao‐Tseng Chen, Ali Osmay Gure, Solam Tsang et al. · Proceedings of the National Academy of Sciences
Open access |
9 Jun 1998 |
295 |
| 43 |
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs et al. · The Lancet Oncology
Open access144 authors |
Feb 2019 |
288 |
| 44 |
Expression of MAGE genes in primary and metastatic cutaneous melanoma
Francis Brasseur et al. · International Journal of Cancer
|
3 Nov 1995 |
287 |
| 45 |
Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED ): an open-label randomised controlled trial
Rolf Wachter et al. · The Lancet Neurology
Open access |
8 Feb 2017 |
286 |
| 46 |
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji et al. · Journal of bone oncology
Open access |
23 Mar 2017 |
281 |
| 47 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Salah Eddin Al-Batran, Joerg Thomas Hartmann, Ralf‐Dieter Hofheinz et al. · Annals of Oncology
Open access |
Aug 2008 |
281 |
| 48 |
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
Jonas S. Heitmann et al. · Nature
Open access |
23 Nov 2021 |
279 |
| 49 |
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo
Elke Jäger, Mark Ringhoffer, Julia Karbach et al. · International Journal of Cancer
Open access |
16 May 1996 |
271 |
| 50 |
A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study
James Andrew Thomas et al. · European Urology
|
14 Aug 2015 |
259 |